• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

KOCHI: Nagarjuna Ayurvedic Group has executed an agreement with Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, to conduct assessment studies of Cardo Guard tablet, a new anti-hypertensive combination drug developed by Nagarjuna.

Besides reducing blood pressure, it is expected to have beneficial effect on the heart by preventing cardio-vascular consequences, a release issued here said. The agreement envisages the assessment of the safety of the drug through toxicity studies; study of the effect of the drug on myocardial mechanics as well as its effectiveness in the regression of hypertrophy.

The project is jointly funded by the Department of Science and Technology, the Nagarjuna Group and SCTIMST. The agreement was signed by Dr K. Mohandas, Director, SCTIMST, and Mr N.V. Subramaniyam, General Manager (Works), Nagarjuna Ayurvedic Group.

More Stories on : Alternative Medicines | Health | Kerala

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
TN likely to achieve windmill power target by year-end

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line